Cancer
Perjeta reduces risk of death
December 11, 2012Sales and Marketing Cancer, Perjeta, Roche
Roche’s cancer drug Perjeta helps reduce the risk of death by 34% in patients with HER2-positive metastatic breast cancer (mBC), …
Avastin shows brain cancer benefit
November 20, 2012Research and Development, Sales and Marketing Cancer, FDA, Merck, Roche, avastin, brain
In a Phase III trial, Roche’s Avastin has helped people with newly-diagnosed glioblastoma (GBM) live longer without their disease worsening. …
Patients ‘shut out’ of drug price talks
November 13, 2012Sales and Marketing Cancer, NHS, NICE, VBP, prostate
Patients are being excluded from the negotiations between government and the pharma industry on the introduction of Value-Based Pricing (VBP).That …
Sanofi criticised for multiple sclerosis manoeuvres
November 2, 2012Sales and Marketing Cancer, Lemtrada, MS, Sanofi
Sanofi is facing a backlash as it prepares its new MS treatment for the market. Lemtrada (alemtuzumab) has produced very …
J&J cancer drugs get EU approval
October 2, 2012Sales and Marketing Cancer, Dacogen, EU, J&J, JJ, Velcade
Two of Johnson & Johnson’s key cancer drugs have been shown the green light from the European Commission. Janssen-Cilag International’s …
Lilly suffers late-stage cancer blow
September 10, 2012Research and Development, Sales and Marketing Alimta, Cancer, avastin, lilly, oncology
Eli Lilly suffered a blow to its oncology programme when a new combination treatment failed to improve overall survival in …
Merck KGaA licences new cancer candidate
September 10, 2012Research and Development, Sales and Marketing Cancer, EGFR, Merck KGaA, oncology
Merck KGaA has signed a worldwide licence agreement with Danish company Symphogen which could expand its portfolio of drugs targeting …
Double approval for Pfizer cancer drugs
September 6, 2012Sales and Marketing CML, Cancer, Glivec, Pfizer, axitinib, rcc
Two cancer drugs from Pfizer have been approved, one in Europe for kidney cancer and another in the US for …
Pfizer to develop phase II cancer vaccine
September 4, 2012Research and Development, Sales and Marketing Cancer, Pfizer, VLST, cancer vaccine
Pfizer has licensed a cancer compound which is ready for phase II study from a US firm specialising in cancer …
J&J buys into Genmab cancer drug
August 31, 2012Sales and Marketing Cancer, Genmab, Janssen Cilag, Janssen-Cilag, Johnson & Johnson, multiple myeloma
Danish biotech company Genmab has sold the worldwide rights for one of its cancer drugs to Johnson & Johnson-owned Janssen …
Novartis and Pennsylvania team up on cancer research
August 6, 2012Research and Development Cancer, Novartis, University of Pennsylvania, chimeric antigen receptor
Novartis and the University of Pennsylvania have joined forces to investigate a method of treating cancer which encourages patients’ immune …
Ariad touts next generation CML treatment
June 29, 2012Research and Development, Sales and Marketing Ariad, CML, Cancer, Europe, Switzerland
Ariad Pharmaceuticals is to expand into Europe following promising results for an investigational cancer drug. The US biotech firm will …
DH admits cancer awareness campaigns failed
June 28, 2012Sales and Marketing Cancer, Department of Health, GPs, government
The government’s £9 million cancer awareness campaigns were built upon failed pilots, according to newly released data. The national awareness …
Afinitor recommended in Europe for breast cancer
June 22, 2012Sales and Marketing Afinitor, CHMP, Cancer, Novartis, breast
A European committee is recommending Novartis’ Afinitor to treat women with a certain type of breast cancer. The CHMP says …
Janssen looks to broaden Zytiga licence
June 18, 2012Sales and Marketing Cancer, Janssen, NICE, Provenge, Zytiga, prostate
Janssen is looking to broaden the licence for its prostate cancer pill Zytiga. Zytiga currently has a US and European …
Latest content
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion
